Company: BWXT
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0001486957-25-000008
Chunk: 69

Company: BWX Technologies, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 1
Chunk 69
---
 delivery systems, nuclear-grade materials and precisely machined components, and related services for CANDU nuclear power plants. This segment also provides a variety of engineering and in-plant services and is a significant supplier to nuclear power utilities undergoing major refurbishment and plant life extension projects. Our in-depth knowledge comes from over 50 years of experience in the design, manufacturing, commissioning and service of nuclear power generation equipment.

Our Commercial Operations segment specializes in performing full-scope, prototype design work coupled with manufacturing integration. This segment's capabilities include:

•steam generation and separation equipment design and development;

•thermal-hydraulic design of reactor plant components;

•in-plant inspection, maintenance and modification services;

•nuclear component modification and replacement;

•commercial nuclear fuel design and manufacturing;

•nuclear fuel handling system design, manufacturing, delivery, installation and commissioning;

•containers for the storage of spent nuclear fuel and other high-level waste;

•structural and thermal-hydraulic design and vibration analysis for heat exchangers;

•structural component design for precision manufacturing;

•materials expertise in high-strength, low-alloy steels and nickel-based materials;

•material procurement of tubing, forgings and weld wire; and

•metallographic and chemical analysis.

This segment also manufactures and supplies products for diagnostic imaging and radiotherapeutic treatments and is a partner for contract development and manufacturing services for life science and pharmaceutical companies. Among its offerings are the manufacture of medical radioisotopes, radiopharmaceuticals and medical devices, as well as partnerships with life science and pharmaceutical companies developing new drugs.

Our Commercial Operations segment's overall activity primarily depends on the demand and competitiveness of nuclear energy and the demand for critical medical radioisotopes and radiopharmaceuticals. A significant portion of our Commercial Operations segment's operations depends on the timing of maintenance outages and the cyclical nature of capital expenditures and major refurbishments for nuclear utility customers, principally in the Canadian market, which could cause variability in our financial results.

2

Table of Contents

Acquisitions

Aerojet Ordnance Tennessee, Inc.

On November 4, 2024, we announced our intention to acquire Aerojet Ordnance Tennessee, Inc. ("A.O.T"), a subsidiary of L3Harris Technologies, Inc. This acquisition was subsequently completed on January 3, 2025. A.O.T is a leading provider of advanced special materials which will further enhance our capabilities to develop and manufacture advanced materials and products for commercial, military and space applications. A